28/02/2026
For National Eating Disorders Awareness Week, we’re sharing what we’re learning from our ongoing studies in the EAT Lab about preventing and treating eating disorders! Today’s insight comes from our GLP-1 Study!
In our GLP-1 study, we found that the prevalence of lifetime use was 2.5x higher among people with eating disorders compared to the general adult population. About 1 in 10 of people with eating disorders reported lifetime misuse of a GLP-1 drug, which included tampering with the syringe, microdosing, accelerating their doses, and sharing with friends or family. These results indicate an emergent pattern of contraindicated GLP-1 use in a high-risk population.